Aetna
Aetna Aetna
Specialty Pharmacy Clinical Policy Bulletins
Aetna Non-Medicare Prescription Drug Plan
Subject: Specialty Quantity Limit Ofev 3211-H P2022

Drug
OFEV  (nintedanib)


Policy:

       I.  PROGRAM DESCRIPTION

            The standard limit is designed to allow a quantity sufficient for
            the most common uses of the medication. The recommended
            dosing parameters for all FDA-approved indications fall within
            the standard limits. Coverage of an additional quantity may be
            reviewed on a case-by-case basis upon request.

 

     II.  COVERED QUANTITIES

   Medication

    Standard Limit

           FDA-recommended dosing

 Ofev (nintedanib)
 capsules 100 mg

 60 per 30 days

 150 mg twice daily (100 mg twice daily in patients with mild
 hepatic impairment)

 

 Dose adjustment for adverse reactions: 100 mg twice daily

 Ofev (nintedanib)
 capsules 150 mg

 60 per 30 days

           


Place of Service:

Outpatient

The above policy is based on the following references:
  1. Ofev [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; October 2020.
Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

June 26, 2022
Aetna
Skip Past Footer Links
Company Information   |   Site Map Aetna.com Home   |   Help   |   Contact Us   |   Search
Web Privacy Statement   |   Legal Statement   |   Privacy Notices   |   Member Disclosure

Back to top